Showing 3981-3990 of 8925 results for "".
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- Candela Launches Dual-Wavelength Vbeam Pro for Vascular and Dermatologic Conditionshttps://practicaldermatology.com/news/candela-launches-dual-wavelength-vbeam-pro-for-vascular-and-dermatologic-conditions/2474321/Candela has introduced its latest pulsed dye laser platform, the Vbeam Pro, at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) in Orlando, Florida.
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Alemtuzumab Highly Effective in CTCL Without Papular History: Analysishttps://practicaldermatology.com/news/study-alemtuzumab-highly-effective-in-ctcl-without-papular-history/2474209/A new analysis suggests the absence of papules, plaques, and tumors (PPT) in cutaneous T-cell lymphoma (CTCL) may predict favorable clinical outcomes with low dose alemtuzumab (LDA) therapy. In a retrospective cohort study
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Global Dermatology Lasers Market Projected to Hit $3.1B by 2029https://practicaldermatology.com/news/global-dermatology-lasers-market-projected-to-hit-31b-by-2029/2474203/The global dermatology lasers market is projected to grow from $2.27 billion in 2025 to $3.1 billion by 2029, according to a market report by The Business Research Company. This growth, according to a press release on the repo
- Metabolomic Signature Predictive of Ocular Side Effects in Dupilumab-Treated AD: Studyhttps://practicaldermatology.com/news/metabolomic-signature-may-predict-ocular-side-effects-in-dupilumab-treated-atopic-dermatitis-study/2474199/New research suggests baseline metabolic differences may help predict which patients with atopic dermatitis (AD) are most likely to develop ocular complications from dupilumab. In findings published in
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo